PharmaTelevision - BioInvent’s Deal with Roche – Are Early-Stage Deals on the Rise?

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: BioInvent’s Deal with Roche – Are Early-Stage Deals on the Rise?

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this interview Fintan Walton speaks with Martin Wiles, Vice President of Business Development of BioInvent International based in Lund Sweden about the deal which Bio Invent has entered into with Roche for their jointly developed anti-cancer agent TB-403. The discussion reveals the qualities which made Roche the ideal partner for this deal, including its expertise in oncology, the fact that the deal was given a good valuation, and the ability for BioInvent to remain involved in the programme throughout its development. Martin describes the potential therapeutic focus of this early-stage product suggesting that it may have implications both within and outside of oncology. The terms of this milestone 450K Euro scheme were discussed, along with the interesting point that one must balance the risk of forming partnerships too early in the stage, and indeed whether larger pharmas are considering early-stage partnerships with increasing interest as part of a broad strategy.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The deal of BioInvent International with Roche

Fintan Walton :

Hello and welcome to PharmaVentures business review here live in San Diego, California. On this show I haveMartin Wiles , who is Vice President of Business Development at BioInvent International Lund, Sweden. Welcome.

Martin Wiles :

Thank you.

Fintan Walton :

Martin Wiles , BioInvent International has just announced a deal, a very important deal with Roche, around a product that was originated from the collaboration that you have with the Belgium company ThromboGenics. Could you tell us about this deal [DOI: 10.3833/pdr.v2008i97.166] that you've just done?

Martin Wiles :

Yeah, sure. Well it's a great deal for both companies ThromboGenics and BioInvent International. And it's a great validation of the approach that we were taking to develop this antibody and 00:01:10 PLGFin presentable growth factors. It's " in terms of the deal structure it's a " it got everything we were looking for. We found a good partner in Roche , they have great expertise in oncology and in particular about Anti-Angiogenesis. We got a good valuation for the deal and we also have an opportunity to remain involved in the program throughout this development. So we, we will " BioInvent International will continue to do manufacturing of antibody for short while. And we will continue to do research for other indications outside of oncology. And additionally right down the line we will hopefully have the opportunity to co-promote in the Benelux and the Nordic, and Baltic states.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Martin Wiles

Vice President of business development

Mr. Martin Wiles serves as Senior Vice President for Business Development of BioInvent International AB. He has been employed by the Company since 2003. Between 1999 and 2003, he was Head of Business Development at KS Biomedix Holdings Plc. He holds a Masters of Business Administration degree and a Doctorate of Philosophy degree in Chemistry.

BioInvent International

BioInvent International is developing human antibody drugs based on unique medical concepts in areas with blockbuster potential such as HIV , vascular diseases (I51.6) and cancer(C00-D48). In total, four different programs are in pre-clinical and clinical phase I/II development. BioInvent International has significant experience and expertise in immunology(D80-D89) that is combined with an extensive understanding of biology.BioInvent International's development focus complements its activities with collaborations with Industry partners and Academic Centers of Excellence such that all parties remain committed to successful development of the products. BioInvent International 's network in the Academic and Biotech community allows for successful sourcing of novel project.n-CoDeR, the proprietary antibody libraries, underpin the discovery and characterization of the fully human antibodies for the portfolio. This coupled with BioInvent International 's capacity to produce materials for clinical trials and at commercial scale provides an infrastructure that can expedite the development process. BioInvent International 's goal is to add maximal shareholder value in the drug development process, either by entering into alliances with pharmaceutical or biotech companies to get projects through late stage clinical development to full commercialization, or by performing the clinical development ourselves.